Immunological study on some of Psoriatic Iraqi PatientsTreated with Etanercept
DOI:
https://doi.org/10.61841/btfs0821Keywords:
Psoriasis, IL17A, IL17AR, Anti-CCP, RFAbstract
The present study is accomplished on (60) patients and (30) healthy individual. Serum levels of (Interleukin 17A (IL17A), Interleukin 17AR (IL17AR)and anticitrullinated protein antibody(ANTI-CCP) is estimated using Enzyme Linked Immunosorbent Assay (ELISA) technique and RF by latex test. Our results were high starting with IL17A mean value before treatment (967.24±784.1), IL17AR (818.62±647.33),ANTI-CCP (33.96±51.82) and with P value of (<0.0001). These levels were reduced significantly after treatment with (Etanercept) injection to give a mean levels of IL17A (360.61±302.38), IL17AR (118.67±191.85), ANTI-CCP (33.98±38.04) and with P value of (<0.0001).Patients were diagnosed with psoriasis arthritis (PsA) by calculating the degree of ANTI-CCP and results were 12 patients before treatment and 17 patients after treatment.ANTI-CCPwas important to diagnose PsA. IL17A, IL17AR have an important role in increasing the inflammation and as a marker for follow up after choosing a treatment in psoriasis and PsA.
Downloads
References
1. Papp K, Pariser D, Catlin M, et al. A phase 2a randomized, double-blind, placebo-controlled,
sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus
kinase inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2015;173(3):767
776.
2. Falodun OA. Characteristics of patients with psoriasis seen at the dermatology clinic of a tertiary
hospital in Nigeria: a 4-year review 2008–2012. J Eur Acad Dermatol Venereol. 2013;27(Suppl.
4)
3. Fuji R, Mould JF J, Tang B, Brandt H, Pomerantz D, Chapnick J et al. (2012) Burden of disease in
patients with diagnosed psoriasis in Brazil: results from 2011 national health and wellness survey
(NHWS). Value Health 15(4): A107.
4. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of
cardiovascular
risk
factors
in
patients
with
psoriasis. J
Am
AcadDermatoldoi:10.1016/j.jaad.2006.08.040. Accessed September 26, 2006.
5. Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, et al. Efficacy and safety of
leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind,
randomized, placebo-controlled clinical trial. Arthritis Rheum 2004;50:1939–50.
6. Lu Y, Chen H, Nikamo P, Qi Low H, Helms C, Seielstad M, et al. Association of cardiovascular
and metabolic disease genes with psoriasis. J Invest Dermatol 2013; 133:836–839.
7. Krueger JG, Brunner PM. Interleukin-17 alters the biology of many celltypes involved in the
genesis of psoriasis, systemic inflammation andassociated comorbidities. Exp Dermatol 2018;
27:115–123.
8. Gaffen, S. L. 2011. Recent advances in the IL-17 cytokine family. Curr. Opin.Immunol. 23: 613
619.
9. Johnston, A., Y. Fritz, S. M. Dawes, D. Diaconu, P. M. Al-Attar, A. M. Guzman,
C. S. Chen, W. Fu, J. E. Gudjonsson, T. S. McCormick, and N. L. Ward. 2013.
Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J. Immunol.
190: 2252–2262.
10. Vander Cruyssen B, Peene I, Cantaert T et al. Anti-citrullinated protein/peptide antibodies
(ACPA) in rheumatoid arthritis: specificity and relation with rheumatoid factor. Autoimmun Rev
2005;4:468–74.
11. Nevitt GJ, Hutchinson PE (1996) Psoriasis in the community: prevalence, severity and patients’
beliefs and attitudes towards the disease. Br J Dermatol 135(4): 533–7.
12. https://www.elabscience.com/p human_il_17(interleukin_17a)_elisa_kit-229289.html
13. https://www.elabscience.com/human-elisa-kits/interleukin-17-receptor-a-il17ra/2021430
14. https://www.elabscience.com/PDF/Cate61/E-EL-H2437-Elabscience.
15. Campa M, Mansouri B, Warren R, Menter A. A review of biologic therapies targeting IL-23 and
IL-17 for use in moderate-to-severe plaque psoriasis. Dermatol Ther (Heidelb) 2016; 6: 1–12.
16. Henseler T, Christophers E (1985) Psoriasis of early and late onset: characterization of two types
of psoriasis vulgaris. J Am Acad Dermatol 13(3): 450–6.
17. Farahnik, B., K. Beroukhim, M. Nakamura, M. Abrouk, T. H. Zhu, R. Singh, K. Lee, T. Bhutani,
and J. Koo. 2016. Anti-IL-17 agents for psoriasis: a review of phase III data. J. Drugs Dermatol.
15: 311–316.
18. Peranteau, A. J., A. E. Turkeltaub, Y. Tong, Z. Nawas, and S. K. Tyring. 2016. A review of
ixekizumab, an anti-interleukin-17A monoclonal antibody, for moderateto-severe plaque psoriasis.
Skin Therapy Lett. 21: 1–6.
19. Balato A, Schiattarella M, Di Caprio R et al. Effects of adalimumab therapy in adult subjects with
moderate-tosevere psoriasis on Th17 pathway. J Eur Acad Dermatol Venereol 2014; 28: 1016–24.
20. Coimbra S, Oliveira H, Neuparth MJ, Proenca JB, Figueiredo A, RochaPereira P, et al. Systemic
inflammation and proinflammatory interleukin-17 signalling persist at the end of therapy in
patients with metabolic syndrome and psoriasis, reducing the length of remission. Br J Dermatol
2016; 174:414–416.
21. Forslind K, Ahlmen M, Eberhardt K, Hafström I, Svensson B, BARFOT Study Group. Prediction
of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to
citrullinated peptides (anti-CCP). Ann Rheum Dis 2004; 63: 1090-5.
22. Yoo IS, Lee JH, Song ST et al. T-helper 17 cells: the driving force of psoriasis and psoriatic
arthritis. Int J Rheum Dis 2012; 15: 531–7.
23. Caproni M, Antiga E, Melani L et al. Serum levels of IL- 17 and IL-22 are reduced by etanercept,
but not by acitretin, in patients with psoriasis: a randomizedcontrolled trial. J Clin Immunol 2009;
29: 210–14.
24. Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results
from a population-based study. Arch Dermatol 2007;143:1493–9.
25. Takahashi H, Tsuji H, Hashimoto Y, Ishida-Yamamoto A, Iizuka H. Serum cytokines and growth
factor levels in Japanese patients with psoriasis. Clinical and Experimental Dermatology
2010;35(6):645-649.
26. Coimbra S, Oliveira H, Neuparth MJ, Proenca JB, Figueiredo A, RochaPereira P, et al. Systemic
inflammation and proinflammatory interleukin-17 signalling persist at the end of therapy in
patients with metabolic syndrome and psoriasis, reducing the length of remission. Br J Dermatol
2016; 174:414–416.
27. A. Michalak-Stoma, A. Pietrzak, J. C. Szepietowski, A. Zalewska-Janowska, T. Paszkowski, and
G. Chodorowska, “Cytokine network in psoriasis revisited,” European Cytokine Network, vol. 22,
no. 4, pp. 160–168, 2011.
28. Kraan MC, van Kuijk AWR, Dinant HJ, Goedkoop AY, Smeets TJM, de Rie MA, et al. Alefacept
treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and
synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum
2002;46:2776–84.
29. Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, et al.
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease:
unexpected results of a randomised, double-blind placebo-controlled trial. Gut (2012)
61(12):1693–700. doi:10.1136/gutjnl-2011-301668
30. Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS et al. Rheumatoid
arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res. 2000;
2(3): 236-43.
31. Martin DA, Towne JE, Kricorian G, Klekotka P, Gudjonsson JE, Krueger JG, Russell CB (2013)
The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J
Invest Dermatol 133:17–26. https://doi.org/10.1038/jid.2012.194
32. Marinoni B, Ceribelli A, Massarotti MS, Selmi C (2014) The Th17 axis in psoriatic disease:
pathogenetic
and
therapeutic
implications.
Auto
Immun
Highlights
5:9
19. https://doi.org/10.1007/s13317-013-0057-4
33. Nirula A, Nilsen J, Klekotka P, Kricorian G, Erondu N, Towne JE, Russell CB, Martin DA,
Budelsky AL (2016) Effect of IL-17 receptor a blockade with brodalumab in inflammatory
diseases. Rheumatology (Oxford) 55:ii43–ii55. https://doi.org/10.1093/rheumatology/kew346
34. Grover C, Kashyap B, Daulatabad D, Dhawan A, Kaur IR. Significance of anti-cyclic citrullinated
peptide autoantibodies in immune-mediated inflammatory skin disorders with and without
arthritis. Indian J Dermatol. 2016;61(5):510–14.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
